Leonid Timashev
Stock Analyst at RBC Capital
(1.10)
# 3,619
Out of 4,876 analysts
86
Total ratings
30.77%
Success rate
-14.3%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Outperform | $16 → $12 | $4.16 | +188.46% | 1 | Jun 25, 2025 | |
| CRMD CorMedix | Reiterates: Outperform | $13 → $17 | $14.96 | +13.64% | 1 | Jun 20, 2025 | |
| ADCT ADC Therapeutics | Maintains: Outperform | $8 → $5 | $2.70 | +85.19% | 1 | Jun 20, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $10 → $6 | $1.97 | +204.57% | 1 | Jun 17, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $193 → $186 | $102.57 | +81.34% | 11 | Jun 12, 2025 | |
| INSM Insmed | Maintains: Outperform | $99 → $106 | $101.74 | +4.19% | 3 | Jun 11, 2025 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $48 | $13.06 | +267.53% | 12 | Jun 5, 2025 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $15 → $16 | $3.62 | +341.99% | 1 | Jun 3, 2025 | |
| BHVN Biohaven | Downgrades: Sector Perform | $54 → $21 | $14.74 | +42.47% | 12 | May 19, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $82 → $80 | $33.91 | +135.92% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $39 → $40 | $28.83 | +38.74% | 2 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.18 | +577.97% | 6 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.24 | +141.94% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $18.45 | +116.80% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $70.81 | -1.14% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $18 | $2.66 | +576.69% | 4 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $86 | $33.48 | +156.87% | 12 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $3.82 | +4.71% | 8 | Aug 6, 2024 |
Verastem
Jun 25, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $4.16
Upside: +188.46%
CorMedix
Jun 20, 2025
Reiterates: Outperform
Price Target: $13 → $17
Current: $14.96
Upside: +13.64%
ADC Therapeutics
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $2.70
Upside: +85.19%
Nuvation Bio
Jun 17, 2025
Maintains: Outperform
Price Target: $10 → $6
Current: $1.97
Upside: +204.57%
Axsome Therapeutics
Jun 12, 2025
Maintains: Outperform
Price Target: $193 → $186
Current: $102.57
Upside: +81.34%
Insmed
Jun 11, 2025
Maintains: Outperform
Price Target: $99 → $106
Current: $101.74
Upside: +4.19%
Edgewise Therapeutics
Jun 5, 2025
Reiterates: Outperform
Price Target: $48
Current: $13.06
Upside: +267.53%
Perspective Therapeutics
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $3.62
Upside: +341.99%
Biohaven
May 19, 2025
Downgrades: Sector Perform
Price Target: $54 → $21
Current: $14.74
Upside: +42.47%
Cytokinetics
May 7, 2025
Maintains: Outperform
Price Target: $82 → $80
Current: $33.91
Upside: +135.92%
May 2, 2025
Maintains: Sector Perform
Price Target: $39 → $40
Current: $28.83
Upside: +38.74%
Mar 19, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.18
Upside: +577.97%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.24
Upside: +141.94%
Jan 24, 2025
Reiterates: Outperform
Price Target: $40
Current: $18.45
Upside: +116.80%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $70.81
Upside: -1.14%
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $2.66
Upside: +576.69%
Dec 9, 2024
Reiterates: Outperform
Price Target: $86
Current: $33.48
Upside: +156.87%
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $3.82
Upside: +4.71%